Schering Corporation

Merck Sharp + Dohme Corp.

Albany Molecular Research, Inc.

Pharmacopeia Drug Discovery, Inc.

Schering Coporation

Pauline C Ting

Robert G Aslanian

Neng-Yang Shih

Kevin D McCormick

Michael Berlin

Rongze Kuang

Christopher W Boyce

Wing C Tom

Jianhua Cao

Daniel M Solomon

Junying Zheng

Heping Wu

John J Piwinski

Xianhai Huang

Younong Yu

Yeon-Hee Lim

Walter Won

Joe F Lee

Amjad Ali

Stuart B Rosenblum

Pietro Mangiaracina

Nicolas Zorn

Gang Zhou

Andrew William Stamford

Dong Xiao

Michael Man-Chu Lo

Manuel De Lera Ruiz

Mwangi W Mutahi

Nicholas I Carruthers

Jae-Hun Kim

Anandan Palani

Joseph Michael Kelly

Ying Huang

Gregory A Reichard

Richard J Friary

Jianhua Chao

Qiaolin Deng

Ashwin Umesh Rao

Paul Tempest

Qingbei Zeng

Henry A Vaccaro

Salem Fevrier

Li Dong

Ning Shao

Hongwu Wang

John J Baldwin

Ashit K Ganguly

Ge Li

Bandarpalle B Shankar

Brian J Lavey

Tin-Yau Chan

Rajan Anand

Timothy J Henderson

Tao Yu

Jayaram R Tagat

Edward Metzger

James J Kaminski

Vera A Seidl

John H Schwerdt

David Kim

Michael P Kirkup

Gioconda V Gallo

Joseph A Kozlowski

Zhaoning Zhu

Brian Alexander McKittrick

Stuart W McCombie

Wensheng Yu

M Arshad Siddiqui

Janeta Popovici-Muller

David J Blythin

Dansu Li

Gerald Wayne Shipps, Jr

Sunil Paliwal

Margaret H Sherlock

Eric J Gilbert

Ho-Jane Shue

Guoqing Li

Purakkattle J Biju

Zhuyan Guo

Robert D Mazzola, Jr

Li Xiao

Vinay M Girijavallabhan

Peter Orth

Xiao Chen

Steven K White

Guowei Zhou

Robert Jason Herr

Lianyun Zhao

Wei Zhou

Tanweer A Khan

Kristin E Rosner

Yonglian Zhang

Chaoyang Dai

David Benjamin Belanger

Scott Trzaska

Frank J Villani

Xiaohong Zhu

Mary Ann Caplen

Hyunjin M Kim

Youhao Dong

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: 'Z' and Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Substituted imidazo[1,2-c]quinazolines as A2A antagonists

The present invention is directed to compounds of generic formula (I): or pharmaceutically acceptable salts thereof that are believed to be useful as an A-receptor antagonist. The invention is further directed to methods of treating a patient (preferably a human) for diseases or disorders in which the A-receptor is involved. The invention further involves use of the compounds as an A-receptor antagonist and/or inhibitor for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the receptor, which includes central nervous system disorders such as Parkinson's disease. The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases. 

Substituted aminoquinazoline compounds as Aantagonist

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: 'Z', Rand Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Aminopyrazine compounds with A2A antagonist properties

Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein 'R', 'R', &#x201c;R&#x201d;, &#x201c;R&#x201d;, and &#x201c;Het&#x201d; are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. 

[object Object]

Disclosed are compounds of Formula G1: where 'R'. 'R' to &#x201c;R&#x201d;, &#x201c;n&#x201d;, &#x201c;m&#x201d;, &#x201c;p&#x201d;, &#x201c;W&#x201d;, &#x201c;X&#x201d;, &#x201c;Y&#x201d;, and &#x201c;Z&#x201d; are defined herein, which compounds are antagonists of Areceptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which Areceptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties

Disclosed are compounds of Formula A: (structurally represented) where 'RG1', 'RG2a', &#x201c;RG4&#x201d;, &#x201c;RG5&#x201d;, &#x201c;MG1&#x201d;, &#x201c;n&#x201d; and &#x201c;m&#x201d; are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. 

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ('DGAT') inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: 

Inhibitors of diacylglycerol acyltransferase

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ('DGAT') inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I). 

Bicyclic compounds as inhibitors of diacylglycerol acyltransferase

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators

Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

Disclosed is a set of compounds useful as glucan synthase inhibitors having the generic structure of Formula I: wherein the various moieties A, D, R, etc., are as defined in the specification. These compounds are useful in treating or preventing fungal infections in a patient.

Pyridazinone derivatives useful as glucan synthase inhibitors

The present invention relates to the compound of the formula To methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.

Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound

The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, R, X, X, R, R, R, R, R, Rand n are as defined in the specification.

Bipiperdine derivatives useful as CCR3 antagonists

Growing community of inventors

New Providence, NJ, United States of America

Pauline C Ting